{
  "docId": "019de073-c7d4-73ef-8fef-22f9b5017668",
  "docSlug": "c95aa30aee69a466f8f903e1480a3b33",
  "documentTitle": "Larimar Therapeutics | Investor Presentation Deck | 32 slides",
  "authorId": "larimar-therapeutics",
  "authorName": "Larimar Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 32,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-c7d4-73ef-8fef-22f9b5017668/16",
  "deckHref": "/decks/019de073-c7d4-73ef-8fef-22f9b5017668",
  "deckJsonHref": "/decks/019de073-c7d4-73ef-8fef-22f9b5017668.json",
  "deckAnchorHref": "/decks/019de073-c7d4-73ef-8fef-22f9b5017668#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.12,
        "y": 0.3
      },
      "kind": "list",
      "text": "Lead candidate: CTI-1601, a recombinant fusion protein designed to deliver frataxin to mitochondria. Orphan Drug (US & EU), Rare Pediatric Disease (US), Fast Track (US), & PRIME (EU) designations for FA.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0dbe7785-2e9c-436c-9c5c-2b7a37710b8c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.12,
        "y": 0.8
      },
      "kind": "list",
      "text": "Strong financial foundation with projected cash runway into 2H 2024. June 30, 2022 cash - $54.9M; September 2022 public offering raised $75M in net proceeds. High-quality institutional investor base includes founding investor Deerfield Management.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3389b93e-2f5e-4c29-843c-09ec4cd4a5f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.85,
        "x": 0.12,
        "y": 0.43
      },
      "kind": "list",
      "text": "Double-blind, placebo-controlled Phase 1 proof-of-concept trials in FA patients complete. Data show dose dependent increases in frataxin (FXN) levels from baseline compared to placebo in all evaluated tissues with daily dosing & that CTI-1601 was generally well tolerated when dosed for up to 13 days.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34dd5b68-85ca-4281-a726-396b057ffc9d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.85,
        "x": 0.12,
        "y": 0.6
      },
      "kind": "list",
      "text": "FDA clearance to initiate a placebo-controlled, Phase 2, 4-week dose exploration study in FA patients. FDA lifted full clinical hold on CTI-1601 and imposed a partial hold, thereby clearing advancement to Phase 2 Cohort 1 to evaluate 25 mg dose; dose escalation contingent on FDA review of cohort 1 data. Study is expected to initiate in Q4 2022, with top-line data from both cohorts in 2H 2023.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c123e4e3-05a2-44a5-b922-0d6061feb0d1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.12,
        "y": 0.15
      },
      "kind": "list",
      "text": "Clinical-stage biotechnology company with a novel protein replacement therapy platform. Focused on addressing unmet needs in Friedreich's ataxia (FA) and potentially other complex rare diseases based on a platform technology backed by a strong intellectual property portfolio.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8518800-2427-4ae6-a3bb-770c06b59a65",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Investment Highlights: CTI-1601 Cleared for Return to Clinic",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76cb578d-7304-4f43-9d6c-21bf054ba1f4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "1af7abe2-f5bb-4f71-8719-57aa0feb3716",
      "evidence": "This slide is titled 'Investment Highlights: CTI-1601 Cleared for Return to Clinic' and contains a list of investment highlights, which is typical of an executive summary.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}